ダウンロード数: 373
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 52_487.pdf | 360.1 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
| DCフィールド | 値 | 言語 |
|---|---|---|
| dc.contributor.author | 西村, 和郎 | ja |
| dc.contributor.author | 高山, 仁志 | ja |
| dc.contributor.author | 中山, 雅志 | ja |
| dc.contributor.author | 野々村, 祝夫 | ja |
| dc.contributor.author | 奥山, 明彦 | ja |
| dc.contributor.alternative | Nishimura, Kazuo | en |
| dc.contributor.alternative | Takayama, Hitoshi | en |
| dc.contributor.alternative | Nakayama, Masashi | en |
| dc.contributor.alternative | Nonomura, Norio | en |
| dc.contributor.alternative | Okuyama, Akihiko | en |
| dc.date.accessioned | 2010-05-25T08:28:45Z | - |
| dc.date.available | 2010-05-25T08:28:45Z | - |
| dc.date.issued | 2006-06 | - |
| dc.identifier.issn | 0018-1994 | - |
| dc.identifier.uri | http://hdl.handle.net/2433/113867 | - |
| dc.description.abstract | Molecular-targeted therapy is to treat pathologic pathways specifically in tumor cell or tumor microenvironment. Specific molecular-targeted therapeutic agents for hormone-refractory prostate cancer (HRPC) include endothelin-A receptor antagonist, EGF receptor (EGFR) inhibitor, platelet derived growth factor receptor (PDGFR) inhibitor, nuclear factor of kappaB (NF-kappaB) inhibitor, cyclooxygenase-2 (COX2) inhibitor, and active form of Vitamin D. These agents have been investigated in clinical trials. So far, none of the above-mentioned agent has shown a sufficient clinical efficacy alone. However, docetaxel-based combinations with thalidomide or calcitriol have promising clinical activities. Further investigations are needed to optimize the molecular-targeted agents in the combinations with chemotherapeutic agents for the treatment of HRPC. | en |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | jpn | - |
| dc.publisher | 泌尿器科紀要刊行会 | ja |
| dc.subject | Hormone-refractory prostate cancer | en |
| dc.subject | Molecular targeted therapy, | en |
| dc.subject.ndc | 494.9 | - |
| dc.title | 再燃性前立腺癌に対する分子標的治療 | ja |
| dc.title.alternative | Molecular-targeted therapy for hormone-refractory prostate cancer | en |
| dc.type | departmental bulletin paper | - |
| dc.type.niitype | Departmental Bulletin Paper | - |
| dc.identifier.ncid | AN00208315 | - |
| dc.identifier.jtitle | 泌尿器科紀要 | ja |
| dc.identifier.volume | 52 | - |
| dc.identifier.issue | 6 | - |
| dc.identifier.spage | 487 | - |
| dc.identifier.epage | 490 | - |
| dc.textversion | publisher | - |
| dc.sortkey | 15 | - |
| dc.address | 大阪大学大学院医学研究科器官制御外科学講座(泌尿器科) | ja |
| dc.address.alternative | The Department of Urology, Graduate School of Medicine, Osaka University | en |
| dc.identifier.pmid | 16848363 | - |
| dcterms.accessRights | open access | - |
| dc.identifier.pissn | 0018-1994 | - |
| dc.identifier.jtitle-alternative | Acta urologica Japonica | la |
| dc.identifier.jtitle-alternative | Hinyokika Kiyo | en |
| 出現コレクション: | Vol.52 No.6 | |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。